5 results match your criteria: "The Kids Research Institute of Australia[Affiliation]"
Leaving No One Behind: Ensuring Adolescents Are Central in Efforts to Address Global Shocks.
J Adolesc Health
December 2024
Adolescent Health and Wellbeing, The Kids Research Institute of Australia, Adelaide, South Australia, Australia; National Centre for Epidemiology and Population Health, Australian National University, Canberra, Australia; Department of Paediatrics, University of Melbourne, Victoria, Australia.
The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-<50 and 50-<70 years old.
J Infect
December 2024
Wesfarmers Centre of Vaccines and Infectious Diseases, The Kids Research Institute of Australia, Nedlands, Australia; Centre for Child Health Research, University of Western Australia, Crawley, Australia; Centre for Child Health Research, University of Western Australia, Crawley, Australia; General Paediatrics and Immunology Departments, Perth Children's Hospital, Nedlands, Australia.
Objectives: PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. Here, we present data for second boosters among individuals aged 18-<50 and 50-<70 years old primed with BNT162b2 until Day (D) 84.
Methods: Immunocompetent adults who had received two doses of BNT162b2 and any licensed COVID-19 booster at least three months prior were eligible.
Trimodal skin health programme for childhood impetigo control in remote Western Australia (SToP): a cluster randomised, stepped-wedge trial.
Lancet Child Adolesc Health
November 2024
Wesfarmers Centre of Vaccines and Infectious Diseases, The Kids Research Institute of Australia (formerly Telethon Kids Institute), University of Western Australia, Nedlands, WA, Australia; Department of Infectious Diseases, Perth Children's Hospital, Nedlands, WA, Australia. Electronic address:
Article Synopsis
- A study was conducted to evaluate the impact of a holistic skin control program, SToP, aimed at reducing impetigo among children in remote communities of the Kimberley, Western Australia.
- The trial involved skin checks, treatment training, and health promotion, targeting children aged 0-18 years in a stepped-wedge randomization process.
- Results showed a significant decline in impetigo cases, particularly noted during initial baseline skin checks prior to the official intervention, with 85% of consented children receiving at least one skin assessment.
Background: Namibia, a low malaria transmission country targeting elimination, has made substantial progress in reducing malaria burden through improved case management, widespread indoor residual spraying and distribution of insecticidal nets. The country's diverse landscape includes regions with varying population densities and geographical niches, with the north of the country prone to periodic outbreaks. As Namibia approaches elimination, malaria transmission has clustered into distinct foci, the identification of which is essential for deployment of targeted interventions to attain the southern Africa Elimination Eight Initiative targets by 2030.
View Article and Find Full Text PDFIdentifying SETBP1 haploinsufficiency molecular pathways to improve patient diagnosis using induced pluripotent stem cells and neural disease modelling.
Mol Autism
September 2024
The Kids Research Institute of Australia, The University of Western Australia, Nedlands, WA, Australia.
Background: SETBP1 Haploinsufficiency Disorder (SETBP1-HD) is characterised by mild to moderate intellectual disability, speech and language impairment, mild motor developmental delay, behavioural issues, hypotonia, mild facial dysmorphisms, and vision impairment. Despite a clear link between SETBP1 mutations and neurodevelopmental disorders the precise role of SETBP1 in neural development remains elusive. We investigate the functional effects of three SETBP1 genetic variants including two pathogenic mutations p.
View Article and Find Full Text PDF